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Summary
Familial combined hyperlipidemia (FCHL) is a common
familial lipid disorder characterized by a variable pattern
of elevated levels of plasma cholesterol and/or triglyc-
erides. It is present in 10%–20% of patients with pre-
mature coronary heart disease. The genetic etiology of
the disease, including the number of genes involved and
the magnitude of their effects, is unknown. Using a sub-
set of 35 Dutch families ascertained for FCHL, we
screened the genome, with a panel of 399 genetic mark-
ers, for chromosomal regions linked to genes contrib-
uting to FCHL. The results were analyzed by use of
parametric-linkage methods in a two-stage study design.
Four loci, on chromosomes 2p, 11p, 16q, and 19q, ex-
hibited suggestive evidence for linkage with FCHL (LOD
scores of 1.3–2.6). Markers within each of these regions
were then examined in the original sample and in ad-
ditional Dutch families with FCHL. The locus on chro-
mosome 2 failed to show evidence for linkage, and the
loci on chromosome 16q and 19q yielded only equivocal
or suggestive evidence for linkage. However, one locus,
near marker D11S1324 on the short arm of human chro-
mosome 11, continued to show evidence for linkagewith
FCHL, in the second stage of this design. This region
does not contain any strong candidate genes. These re-
sults provide evidence for a candidate chromosomal re-
gion for FCHL and support the concept that FCHL is
complex and heterogeneous.
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Introduction
Familial combined hyperlipidemia (FCHL; MIM
144250), with a frequency of ∼1% in U.S. and European
white populations, is the most common genetic lipid
disorder observed in patients with coronary heart disease
(CHD) and in their relatives. It occurs in 10%–20% of
patients with premature CHD and is characterized by
elevated concentrations of plasma triglycerides (190th
percentile) and/or plasma cholesterol (190th percentile)
in probands and their affected relatives (Goldstein et al.
1973; Nikkila and Aro 1973; Rose et al. 1973; Brunzell
et al. 1983). Although FCHL was first described 125
years ago, its primary etiology remains unknown. The
disease was first postulated to have a Mendelian-dom-
inant pattern of transmission, but subsequent segrega-
tion analyses suggested a more complex inheritance pat-
tern (Iselius 1981; Williams and Lalouel 1982; Cullen
et al. 1994). To date, hypotheses regarding the under-
lying mode of inheritance of FCHL have been made on
the basis of segregation analyses and remain to be cor-
roborated by identification of the contributing loci and
genes. Lipoprotein metabolism in patients with FCHL
is characterized by an overproduction of hepatic apo-
lipoprotein (apo) B–containing lipoproteins, resulting in
increased plasma levels of LDL and of very-low-density
lipoproteins (VLDL) (Kissebah et al. 1981; Cortner et
al. 1991; Venkatesan et al. 1993; Aguilar-Salinas et al.
1997). Defects in lipoprotein clearance (Cabezas et al.
1993; Yang et al. 1996), glucose intolerance (Vakkilai-
nen et al. 1998), reduced peripheral triglyceride synthesis
(Cianflone et al. 1995), insulin resistance (Aitman et al.
1997), and reduced adipocyte lipolysis (Reynesdottir et
al. 1995) have also been implicated.
Candidate-gene studies have provided evidence that
common variations of several genes, including lipopro-
tein lipase (LPL) and the apoAI-CIII-AIV cluster, can
influence lipid levels in affected individuals, but none of
these appear to be a primary genetic determinant (Woj-
ciechowski et al. 1991; Dallinga-Thie et al. 1996, 1997;
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Yang et al. 1996; Pajukanta et al. 1997; Aouizerat et
al., in press). Recent studies of the Finnish isolate re-
vealed a locus near the candidate gene apoAII, on human
chromosome 1, that appears to contribute to FCHL (Pa-
jukanta et al. 1998). Strong support for this locus comes
from the mapping of a gene for combined hyperlipide-
mia to a region of conserved synteny on mouse chro-
mosome 3 (Castellani et al. 1998).
Linkage studies of FCHL pose a considerable chal-
lenge, partly because the disorder lacks unequivocal di-
agnostic criteria. The original diagnosis of FCHL was
given on the basis of premature CHD and evidence of
three different lipid phenotypes among the first-degree
family members: elevated cholesterol (phenotype IIA),
elevated cholesterol and triglycerides (phenotype IIB,
combined hyperlipidemia), or elevated triglycerides
(phenotype IV) (Goldstein et al. 1973; Nikkila and Aro
1973). In addition, hyperlipidemia is quite variable
among affected individuals and can also vary, over time,
for an individual. Hyperlipidemia is age dependent, since
children usually exhibit only modest elevations of cho-
lesterol and triglycerides. Compounding these difficulties
is the lack of a genetic model that adequately reflects
the clear familial inheritance of the disease. These prob-
lems make it difficult to apply traditional model-based
linkage approaches, which have been used successfully
for mapping genes causing monogenic disorders (Hanis
et al. 1996).
In the present study, we report the results of a ge-
nomewide screen for FCHL-susceptibility genes, using
nonparametric-linkage approaches and a two-stage de-
sign. In stage 1, a complete multipoint genome scan was
done in 240 individuals in nuclear families from 18
Dutch FCHL families, with use of 399 genetic markers
spanning ∼10-cM intervals. Four regions with suggestive
LOD scores between 1.0 and 3.0 were identified. These
four loci were examined subsequently in 782 individuals,
extending the number of pedigrees to 35. Three of the
loci exhibited only suggestive or no evidence for linkage
in the stage 2 analysis. However, a region on the short
arm of chromosome 11 continued to exhibit evidence
for linkage when the additional sampled families were
analyzed. Since only modest LOD scores were observed
for any loci in this relatively large family study, the data
are not consistent with a model in which the disease is
due to a single major gene. Thus, these results also pro-
vide strong evidence for the genetic complexity of FCHL,
supporting previous segregation analyses. The novel
FCHL locus on chromosome 1q21-q23, identified in the
Finnish isolate (Pajukanta et al. 1998), did not exhibit
strong evidence for linkage in the present study of the
Dutch outbred population. These observations imply
that FCHL not only is multigenic but also is heteroge-
neous in nature.
Families and Methods
Ascertainment of FCHL Families
Dutch FCHL families were ascertained as described
elsewhere (Dallinga-Thie et al. 1996, 1997) and exhibit
remarkable similarity with the original description of
FCHL (Goldstein et al. 1973). The probands with FCHL
were identified through a lipid-out patient clinic in a
tertiary academic referral center. Although all are of
Dutch descent, the recruited FCHL families are not from
a single geographic area in the Netherlands. Initially, 18
unrelated probands with FCHL were recruited through
the Lipid Clinic of the Utrecht University Hospital; sub-
sequently, 17 additional probands were identified. The
probands met three criteria, as follows: (1) primary hy-
perlipidemia, with plasma cholesterol 1250 mg/dl (16.5
mmol/liter), triglycerides 1200 mg/dl (12.3 mmol/liter),
and apoB concentrations exceeding, by 2 SD, the mean
for age-adjusted levels; (2) at least one first-degree rel-
ative with a different hyperlipidemic phenotype; and (3)
a positive family history of premature CHD, defined as
myocardial infarction or cardiovascular disease with age
at onset !60 years. Exclusion criteria for probands in-
cluded diabetes, obesity (body-mass index [BMI] 128),
familial hypercholesterolemia (tendon xanthomas), and/
or type III hyperlipidemia (apoE2/E2). Low HDL-cho-
lesterol level was not used as a trait for ascertainment,
since it was observed in only a subset of the FCHL fam-
ilies. All subjects gave informed consent, and the study
protocol was approved by the Human Investigation Re-
view Committee of the University Hospital, Utrecht.
The pedigree structures and clinical characteristics of
the 35 FCHL families are shown infigure 1and table 1,
respectively. Relatives and spouses of probands were re-
cruited without bias with regard to affectation status,
and 195% of all available living relatives of probands
were studied. Hyperlipidemic family members (n 
) were assigned an FCHL phenotype on the basis of253
presenting with plasma cholesterol and/or plasma tri-
glycerides 190th percentile and/or apoB 175th percen-
tile, for age-matched and gender-matched controls. Fam-
ily members who did not meet these criteria were
classified as normolipidemic ( ). A spouse groupn  298
( ) provided unrelated controls matched for en-n  232
vironment, nutrition, and age. These criteria are likely
to provide reasonable estimates of normal values for the
defining diagnostic criteria (i.e., levels of total choles-
terol, triglycerides, LDL-cholesterol, apoB, and HDL-
cholesterol). The age of probands was ∼51 years (range
27–76 years); 24% were female, as compared with 45%
of affected individuals identified in the entire sample.
The large proportion of male probands is in part the
result of an ascertainment bias, since CHD affects men
earlier than women, regardless of the underlying etiol-




Figure 1 Pedigree structures of the 35 Dutch FCHL families. Hypertriglyceridemic individuals (i.e., with plasma triglyceride levels 190th percentile) are denoted by upward diagonal hatching.
Hypercholesterolemic individuals (i.e., with plasma cholesterol levels 190th percentile) are indicated by downward diagonal hatching. Individuals who are both hypercholesterolemic and hypertri-
glyceridemic are denoted by a cross-hatching. Individuals genotyped in the stage 1 genome scan are indicated by an “s” below the symbol.
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Table 1
Clinical Characteristics of the FCHL Families
VARIABLE
MEAN  SD IN
Hyperlipidemic
Individualsa
(n  253)
Normolipidemic
Individuals
( )n  298
Spouse
Controls
( )n  231
Age (years) 4916 3415 4815
Lipids (mg/dl):
Triglycerides 243143 11643 14491
Cholesterol 28190 19131 21940
LDL-cholesterol 17953 12229 14438
apoB 13130 8422 102 8
apoCIII 11.84.2 7.42.5 8.73.2
a Includes the 35 probands and 218 hyperlipidemic individuals.
ogy. The hyperlipidemic relatives had characteristics sim-
ilar to those of the probands, including a male prepon-
derance (55%), as well as higher values for BMI and
waist-hip ratio than were seen in normolipidemics (Dal-
linga-Thie et al. 1996). Normolipidemic relatives were
younger than the hyperlipidemic relatives, and it is likely
that the FCHL phenotype had not yet been fully ex-
pressed in some normolipidemic individuals. Although
children with FCHL exhibit somewhat elevated plasma
lipid values, the age at onset of the FCHL phenotype
has been assumed to be 120 years (Goldstein et al. 1973;
Castro Cabezas et al. 1992).
Analytic Methods
Venous blood was drawn after an overnight fast of
12–14 h, and plasma was prepared by immediate cen-
trifugation. Lipids and apo were quantified by use of
methods described elsewhere (de Bruin et al. 1991; Ca-
bezas et al. 1993; Dallinga-Thie et al. 1996). Probands
or hyperlipidemic relatives who used lipid-lowering
drugs were sampled after their lipid-lowering treatment
was withheld for 3 wk. Only these lipid values and other
quantitative measurements were used in this study. Hor-
mone-replacement therapy showed little effect on lipid
traits in this Dutch FCHL sample and therefore was not
considered a confounding factor (T. W. A. de Bruin,
unpublished data). Alcohol use was not controlled for,
beyond the subjects’ abstention from alcohol consump-
tion for 48 h prior to having blood drawn.
Genotyping
In the present study, DNA from 782 subjects (Dal-
linga-Thie et al. 1996, 1997) was used for analysis. DNA
was isolated from 10 ml EDTA-augmented blood, by
use of standard procedures (Weber and May 1989). Ge-
notyping was performed either manually, with use of
radiolabeled PCR products (Allayee et al. 1998), or with
the aid of a scanning fluorescent detector, with use of
fluorescently labeled PCR products (Yuan et al. 1997).
For fluorescent genotyping, the final PCR reaction con-
ditions were as follows: 100 mM each of dGTP, dATP,
dTTP, and dCTP; 0.075 mM each PCR primer (Research
Genetics; forward primer labeled with fluorescent dye);
45 ng genomic DNA template; and 0.12 U AmpliTaq
Polymerase (Boehringer Manheim), in a final volume of
4 ml. Amplified products were resolved by electropho-
resis with 6.0% polyacrylamide gels containing 7.7 M
urea, 89 mM Tris, 89 mM borate, and 2.5 mM EDTA
and were visualized by a scanning fluorescence detector
(Rusch et al. 1996). The 399 markers used in the con-
struction of the genome-screen linkage map constituted
the Weber 6 screening set (Marshfield Medical Research
Foundation).
Linkage Analysis
Since FCHL is thought to have a complex pattern of
inheritance, we analyzed data from the genome screen
by using nonparametric linkage (NPL) methods that do
not require assumptions regarding the mode of inheri-
tance (Ott 1991). The primary screen was done with use
of the multipoint linkage analysis program MAP-
MAKER/SIBS, which uses information from multiple
linked markers to calculate allele sharing at and between
markers determined on the basis of the most likely gen-
otypes (Kruglyak and Lander 1995). Significance of the
test statistic for excess allele sharing among affected sib-
ling pairs is expressed as a LOD score (Ott 1991; Krug-
lyak and Lander 1995). In addition, this analytic meth-
odology mitigates, in part, the potential effect of markers
with low heterozygosity indices, since the informative-
ness of a locus is also calculated with linked markers.
In stage 2, regions with suggestive LOD scores (i.e.,
between 1.0 and 3.0) were examined in 782 individuals,
extending the number of pedigrees to 35. Polymorphic
markers at the four loci detected in stage 1 were typed
in the second set of individuals (with use of the peak
marker from the stage 1 scan and an additional closely
linked marker), and P values, calculated by two-point
allele-sharing methods (Haseman and Elston 1972; Els-
ton 1997), for the entire sample were compared with
those of the initial sampled pedigrees in stage 1. The
recent observation that a particular set of markers for
genomewide scanning will have different informative-
ness among ethnic groups suggests that use of allele fre-
quencies from the study population, rather than pub-
lished frequencies, is appropriate (Hegele et al. 1998).
Therefore, spousal genotype data were used to calculate
allele frequencies for markers analyzed in stage 2. Al-
though the allele frequencies observed in the Dutch
FCHL sample varied slightly from those distributed
through the CEPH database (Ge´ne´thon), they were not
substantially different. None of the markers’ heterozy-
gosity indices differed 1.15 from the CEPH panel, and
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184% of the markers varied !.05. In addition, spousal
genotypes were used to confirm Mendelian inheritance
for marker alleles. Families with bilineal inheritance (i.e.,
a spouse with an expressed Fredrickson type IIB hyper-
lipidemic profile) were excluded from statistical analysis.
To assess linkage in the sample of clinically concor-
dant affected sibling pairs, we calculated the mean allele
sharing at the loci of interest and tested each allele for
a significant difference from the expected value of ran-
dom allele sharing (.50), by using the SIBPAL subpro-
gram of the SAGE package (Elston 1997). A significant
increase in allele sharing (1.50) was taken as evidence
for linkage. The advantage of an initial analysis that uses
only affected sibling pairs is that each person in the
analysis is assumed to have the disease gene of interest,
and other apparently unaffected individuals who may
have the gene but who have not expressed the trait do
not confound the results. Because a specific hypothesis
was being tested with each of these loci, a P ! .05 was
chosen to support our further analysis of the data. In
addition to single-marker analyses, haplotypes derived
from combinations of markers from the selected can-
didate regions were also used, to maximize the linkage
information available in the extended stage 2 sample.
When the sample of affected sibling pairs in the se-
lected candidate regions exhibited evidence for linkage,
we extended the analyses to include two additional
groups of sibling pairs, one in which both were unaf-
fected (clinically concordant unaffected sibling pairs)
and another in which one was affected and the other
was unaffected (clinically discordant sibling pairs). At
linked markers, both concordant affected and concor-
dant unaffected sibling pairs are expected to demon-
strate increased sharing of marker alleles identical by
descent (IBD), whereas clinically discordant pairs should
exhibit decreased sharing. However, both concordant
unaffected and discordant sibling pairs should show
weaker evidence for linkage than do affected sibling
pairs, because some unaffected siblings may carry the
disease gene but not express the phenotype, because of
a lack of other genetic and/or environmental factors that
contribute to the development of the disease (Thomson
1994).
Data from all three groups of sibling pairs were also
combined into a linear-regression analysis with use of
SIBPAL, which regresses the trait differences (disease
status) between sibling pairs versus the proportion of
marker alleles that they share IBD. A significantly neg-
ative regression-line slope indicates that those who are
phenotypically alike tend to share more alleles, whereas
those who are discordant tend to exhibit less allele shar-
ing, thus providing evidence for linkage. In the absence
of linkage, the slope of the regression line is not expected
to be significantly different from zero. The linear-re-
gression analysis was also done with haplotypes of
markers from selected candidate regions.
The quantitative traits associated with FCHL (levels
of total plasma triglycerides, LDL-cholesterol, apoB,
apoCIII, and HDL-cholesterol) were analyzed in a sim-
ilar fashion. All quantitative analyses were done initially
on untransformed data, and logarithmically transformed
data were analyzed when the quantitative-trait distri-
bution was skewed. The effects of gender and age on
plasma LDL-cholesterol, triglyceride, apoB, apoCIII,
and HDL-cholesterol levels accounted for a small
amount of the variability in the traits ( ). Ac-2r ! 10%
cordingly, they were not used as covariates.
In an attempt to define criteria that better reflect
FCHL affectation status, two new quantitative pheno-
types were assessed as intermediate phenotypes. One,
the ratio of total triglycerides to apoCIII, has been shown
to be decreased in individuals with FCHL (van Barlingen
et al. 1996). To better represent the source of elevated
cholesterol in individuals with FCHL, non-
HDL–cholesterol levels were used as another interme-
diate phenotype.
Assessing the Degree of Heterogeneity at the
Chromosome 11 Locus
To test for genetic heterogeneity, both an affected-
sibling-pair analysis (which disregards parental pheno-
type) and a parametric LOD-score analysis (which uses
parental phenotypic information) were done, with a
peak marker (D11S1324) at the chromosome 11 locus.
The GENEHUNTER program calculates an NPL sta-
tistic and the corresponding relative informativeness of
the genotypic data for the families (Kruglyak et al. 1996;
Kruglyak and Lander 1998). The NPL statistic is a
model-free measure of allele sharing (a Z score). A par-
ametric LOD-score analysis was also performed on the
component nuclear families as if they were independent,
with use of the LINKAGE package programs (v. 5.1,
updated by J. Ott; Lathrop et al. 1984; Ott 1991) and
the POLYPREP program (Terwillinger and Ott 1994)
with FASTLINK (v. 2.3P; Lathrop et al. 1984, 1986;
Cottingham et al. 1993; Schaffer et al. 1994). In our
analysis, a LOD score was first calculated with the as-
sumption of homogeneity at the locus, and a second
LOD score was calculated with the assumption of het-
erogeneity. To circumvent problems of incomplete pen-
etrance and the genetic ambiguity of an “unaffected”
phenotype, we used an affecteds-only strategy by coding
the subjects as either “affected” or “unknown” (Paju-
kanta et al. 1997). POLYPREP (Terwillinger and Ott
1994), which contains the program HOMOG, was used
to test for possible heterogeneity for FCHL at marker
D11S1324.
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Table 2
Maximum Multipoint LOD Scores for Each Chromosome in the Genome Scan
for FCHL
Chromosome
Maximum
LOD Scorea
Nearest
Markerb
Distance
from pter
(cM)
Information
Content
Allele
Sharing
1 1.0 D1S1597 21 .7 .52
2 2.6 D2S2952 16 .7 .62
3 .7 D3S1766 84 .6 .56
4 .6 D4S2639 21 .8 .53
5 .7 D5S1505 140 .8 .54
6 .8 D6S1021 111 .8 .50
7 .1 D7S513 14 .8 .56
8 .3 D8S1106 24 .6 .54
9 .2 D9S1121 33 .8 .52
10 .8 D10S1213 155 .5 .53
11 2.6 D11S1985 62 .6 .55
12 .6 D12S2078 150 .6 .50
13 .5 D13S800 53 .7 .59
14 .6 D14S306 36 .6 .53
15 .7 D15S655 75 .5 .53
16 1.4 D16S402 106 .8 .53
17 .1 D17S2180 100 .8 .48
18 .6 D18S1357 90 .8 .52
19 1.3 D19S589 88 .5 .52
20 .3 D20S171 90 .7 .54
21 .1 D21S1432 0 .6 .52
22 .1 D22S420 0 .5 .53
X .9 DXS6800 93 .5 )
a Maximum multipoint LOD scores were calculated with use of the MAP-
MAKER/SIBS program.
b Information for individual markers in the genome scan is provided at the Marsh-
field Center for Human Genetics Website.
Results
Study Design
Previous candidate-gene studies have failed to identify
the genetic factor(s) that can account for overproduction
of VLDL, the metabolic hallmark of FCHL. To map the
principal genes involved and to examine the complexity
of the disease, a genome scan was done in families as-
certained for FCHL. Since previous modeling has sug-
gested that FCHL is a complex disorder (Williams and
Lalouel 1982), we primarily have used nonparametric
(model-free) strategies for analyzing linkage data. Be-
cause a genome scan involves multiple testing, it is likely
that some loci exhibiting modest LOD scores (1.0–3.0)
will result by chance alone. To address this possibility,
a two-stage study design was adopted.
In stage 1, a complete genome scan was done in 240
individuals in nuclear families from 18 Dutch FCHL
families and then was analyzed with use of nonpara-
metric multipoint methods (MAPMAKER/SIBS pro-
gram; Kruglyak and Lander 1995). In stage 2, regions
with suggestive LOD scores were examined by genotyp-
ing polymorphic markers at the loci detected in stage 1
in 17 additional families, thus extending the number of
pedigrees to 35 (782 individuals). P values were then
calculated by use of two-point allele-sharing methods
(Elston 1997) for the entire sample and were compared
with those of the initial sampled pedigrees in stage 1.
Loci harboring FCHL genes are expected to attain or
improve the stage 1 level of significance for the region,
whereas loci observed by chance in stage 1 are expected
to exhibit reduced significance.
Stage 1 Analysis
The complete linkage map consisted of 399 markers
spanning ∼10-cM intervals (Yuan et al. 1997). All 22
autosomes and the X and Y chromosomes were typed,
and the heterozygosity of the markers averaged .82 in
the families analyzed. Table 2 presents the maximum
LOD score obtained for each chromosome, along with
the marker nearest to the peak. In the initial scan, no
locus with a LOD score 13.0 was identified; two loci
(on chromosomes 2 and 11) had LOD scores 12.0, and
two other loci (on chromosomes 16 and 19) had LOD
scores 11.0. Figure 2 shows the multipoint analyses of
the four chromosomes exhibiting suggestive LOD scores.
All four loci with LOD scores 11.0 were examined fur-
ther. A locus for FCHL identified in the Finnish isolate
(Pajukanta et al. 1998) did not show evidence for linkage
in the Dutch pedigrees, although a modest peak for tri-
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Table 3
Two-Point Linkage Analyses in Regions Showing Multipoint LOD
scores 1 1.0 in the Genome Scan
CHROMOSOME
AND MARKER
STAGE 1 STAGE 2
No. of
ASPa
Allele
Sharing P
No. of
ASPa
Allele
Sharing P
2:
D2S2952 79 .62 .0005 206 .51 .23
D2S319 ) ) ) 162 .48 .82
11:
D11S1985 81 .55 .06 116 .56 .02
D11S1324 ) ) ) 181 .55 .01
16:
D16S402 77 .53 .21 151 .56 .01
D16S516 ) ) ) 167 .51 .40
19:
D19S589 81 .52 .25 179 .53 .10
D19S927 ) ) ) 200 .51 .01
a ASP  affected sibling pairs. The number of informative sibling
pairs (of the possible 115 ASP genotyped) is given.
Figure 2 Potentially linked loci ( ) identified in the genome scan of 18 FCHL families. Multipoint plots for chromosomes 2, 11,n  240
16, and 19 (A, B, C, and D, respectively) were obtained with use of the MAPMAKER/SIBS program. The chromosome length spanned by
genetic markers on chromosomes 2, 11, 16, and 19 are 294, 147, 124, and 94 cM, respectively. The locations of genetic markers typed for
each chromosome are indicated at the bottom of each plot. Intrachromosomal genetic distances and additional genetic marker information are
available at the Marshfield Center for Human Genetics Website.
glyceride levels ( ) was observed (data notLOD  1.0
shown).
We also tested for linkage several quantitative traits
associated with FCHL, including total plasma levels of
triglycerides, LDL-cholesterol, apoB, apoCIII, and HDL-
cholesterol, as well as two empirically derived inter-
mediate phenotypes, the triglyceride-to-apoCIII ratio
and non-HDL-cholesterol levels (described in Families
and Methods). Analysis of these component quantitative
traits and derived phenotypes in the genome scan failed
to produce LOD scores 1 1.0 that were coincident with
any of the four suggestive regions identified for the qual-
itative FCHL phenotype (data not shown). This finding
is consistent with the concept that the combined param-
eters for the disorder may be a better diagnostic indicator
than individual lipid or apo levels.
Stage 2 Analysis
The suggestive loci identified in the multipoint genome
scan were further examined in the entire set of pedigrees
comprising 35 families and 782 individuals. At each of
the four loci, the peak marker and an additional closely
linked marker were typed in all family members (table
3). A direct comparison of the results from the initial
genome-scan linkage analysis with the results from the
eight markers typed in the entire population was not
possible. The MAPMAKER/SIBS program evaluates
multipoint linkage at a locus by using marker infor-
mation along the whole chromosome, which was avail-
able only for the 240 individuals in the genome scan.
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Figure 3 Linear-regression analysis, for chromosome 11 hap-
lotypes with FCHL. Negative regression of squared-trait differences
for FCHL versus the number of marker alleles shared IBD are shown.
The number of sibling pairs sharing zero, one, or two alleles IBD is
151, 289, and 146, respectively.
Therefore, a two-point linkage analysis was used to ex-
amine the extended population (Elston 1997). The peak
LOD-score marker within each of the four loci identified
by the genomewide scan was first reanalyzed with use
of two-point allele-sharing estimates in the affected sib-
ling pairs. We evaluated the entire population for linkage
by using the same two-point method, which made it
possible to compare the results from the genome scan
directly with the results from the entire population.
Table 3 shows the two-point linkage results for mark-
ers typed at these loci. For each marker, the mean allele
sharing and the result of the test for its difference from
.50 is given, expressed in terms of a P value. When
extended from the initial sample, the locus on chro-
mosome 2 exhibited a decrease in allele sharing and a
nonsignificant linkage test for both markers (table 3). In
the extended pedigrees, the degree of allele sharing
among affected siblings at the chromosome 16 locus was
significant at one marker (D16S402; ) but notP  .01
at the other marker (D16S516; ). Similarly, atP  .40
the chromosome 19 locus, one marker yielded evidence
for linkage (D19S927; ), whereas the peak LOD-P  .01
score marker did not exhibit significant linkage
(D19S589; ). In contrast, at the chromosomeP  .10
11p locus, the peak marker yielded evidence for linkage
(D11S1985; ), as did the other nearby markerP  .02
not typed in the genome scan (D11S1324; ). OnP  .01
the basis of these data, the chromosome 11 locus was
further examined for evidence of linkage and potential
genetic heterogeneity.
Evaluating Evidence for an FCHL Locus on
Chromosome 11
To further evaluate the chromosome 11 locus, we
typed additional markers to better define the peak lo-
cation of the putative FCHL gene. In addition to an
affected-sibling-pair analysis, we also performed a lin-
ear-regression analysis with these markers, using all
available sibling pairs. As shown in table 4, the peak
linkage in both analyses was observed with marker
D11S1324. To maximize the informativeness of the re-
gion, we also constructed haplotypes by using the mark-
ers surrounding the peak (D11S1324, D11S1392, and
D11S1985) and tested the haplotypes for linkage by us-
ing both the mean-allele-sharing test and the regression
test (table 4). The affected sibling pairs demonstrated a
significant mean allele sharing of .56, and the two-point
P values increased in significance for the haplotype
( ), compared with the individual markers (tableP  .004
4). When all available sibling pairs were used in the
linear-regression analysis, evidence for linkage with the
haplotype was also observed ( ; fig. 3). This PP  .002
value corresponds to a LOD score of ∼1.9. The fact that
it is lower in magnitude than the peak LOD score of 2.6
observed, for chromosome 11, in the original scan pre-
sumably relates to the fact that it is based on a haplotype
of three markers rather than on the increased power of
a complete multipoint analysis. Furthermore, the clini-
cally discordant sibling pairs (one affected and one un-
affected) exhibited a significantly decreased mean allele-
sharing of .44 ( ) for the haplotype, consistentP  .007
with linkage of FCHL to this region.
The possibility exists that FCHL is genetically heter-
ogeneous (Williams and Lalouel 1982; Aouizerat et al.
1999a). Using the peak marker at the chromosome 11
locus, D11S1324, we analyzed individual families to test
for heterogeneity. The families were initially analyzed
nonparametrically with GENEHUNTER (Kruglyak et
al. 1996; Kruglyak and Lander 1998), which, analogous
to SIBPAL, assesses the degree of allele sharing, among
affected sibling pairs, at a marker locus. An advantage
of GENEHUNTER for these nonparametric analyses is
that it provides an estimate of the relative informative-
ness, for each family, at the marker locus. No evidence
of genetic heterogeneity was observed at the chromo-
some 11 locus (data not shown). However, because non-
parametric approaches have relatively low power for
detection of linkage and heterogeneity (Ott 1991), a par-
ametric analysis was also done. Parametric analyses re-
quire the specification of a mode of inheritance, disease-
allele frequency, and degree of penetrance. For the
purposes of these analyses, the mode of inheritance was
assumed to be dominant, as originally suggested for
FCHL (Goldstein et al. 1973), and on the basis of a
population prevalence of 1%—2%, the disease-allele
frequency was set at 0.6%. We adopted an affecteds-
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Table 4
Two-Point Sibling-Pair-Linkage Analysis Results, for Chromosome
11 Markers and FCHL
MARKER
DISTANCEa
(CM)
ASPb ANALYSIS
LRc
ANALYSIS
No. of
ASP
Allele
Sharing Pd Edfe Pd
D11S1999 17 159 .52 .25 221 .05
D11S1981 29 162 .52 .16 229 .44
ATA34E08 37 165 .54 .05 245 .04
D11S1324 41 181 .55 .01 247 .002
D11S1392 50 208 .54 .02 266 .06
D11S1985 65 116 .56 .02 183 .01
D11S2371 75 160 .51 .40 221 .25
D11S2002 85 131 .52 .17 218 .61
Haplotypef ) 219 .56 .004 291 .002
a From pter of chromosome 11.
b ASP  affected sibling pairs.
c LR  linear regression.
d Significant P values are underlined.
e Edf  effective df.
f The haplotype was constructed with use of markers D11S1324,
D11S1392, and D11S1985.
only approach, and therefore the penetrance was set at
100%. A LOD-score–based statistic, generated by PO-
LYPREP, was used to test for heterogeneity of FCHL at
this locus. The total LOD score for this analysis with
the assumption of heterogeneity did not deviate signif-
icantly from the original parametric analysis with the
assumption of homogeneity (DLOD ! 0.12; data not
shown), thus providing no significant evidence of het-
erogeneity at marker D11S1324.
Discussion
The molecular and genetic factors contributing to
FCHL have remained largely unknown since the dis-
covery of the trait, 125 years ago. Originally, FCHL was
postulated to exhibit an autosomal dominant Mendelian
pattern of inheritance (Goldstein et al. 1973), but sub-
sequent analyses have suggested a more complex pattern
(Williams and Lalouel 1982; Jarvik et al. 1993; Cullen
et al. 1994; Bredie et al. 1997b Aouizerat et al. 1999a).
Physiological and molecular studies have provided evi-
dence that abnormalities associated with FCHL include
overproduction of VLDL, altered lipid metabolism in
peripheral tissues, and reduced catabolism of triglycer-
ide-rich lipoproteins. Candidate-gene studies have iden-
tified possible modifier genes for FCHL, including var-
iations of the LPL gene on chromosome 8 (Yang et al.
1996) and the apoAI-CIII-AIV gene cluster on chro-
mosome 11 (Dallinga-Thie et al. 1997). We now report
a genome scan for FCHL, done in a series of Dutch
pedigrees. The results provide evidence for at least one
locus that may harbor a gene(s) for FCHL. Furthermore,
these results also support the notion that the genetic
architecture of the disease is complex, which is consistent
with previously reported segregation analyses.
Our comprehensive genome screen identified two loci
with LOD scores 12.0 and two loci with LOD scores
1.0–2.0. Because of the extensive number of linkage tests
involved, we assumed that at least one of these loci was
likely to have occurred by chance. Therefore, we typed
markers at each of these four loci in 542 additional
family members to test which, if any, would continue to
exhibit evidence of linkage. The chromosome 2 locus
failed the test of replication. The chromosome 16q and
19q results were suggestive and merit further investi-
gation. However, the results for chromosome 11p were
supportive, since the P values of markers typed in the
region improved with the additional families examined.
Moreover, typing additional markers in the region al-
lowed haplotype analysis, which provided stronger ev-
idence for linkage. The only obvious candidate gene re-
lated to lipid metabolism, identified in the 11p region,
is that for the oxysterol-binding protein (OSBP; Entrez
Database), which binds a range of biologically active
sterols, including 25-hydroxysterol (Dawson et al. 1989;
Levanon et al. 1990). However, recent studies of the role
of OSBP in cellular cholesterol metabolism suggest that
it is unlikely to underlie the FCHL trait (Ridgway et al.
1998; Storey et al. 1998; Lagace et al. 1999).
There was no evidence for genetic heterogeneity in the
nonparametric analysis when the chromosome 11 locus
(D11S1324) was tested. It is possible that the variability
of these pedigree structures (fig. 1) may not permit its
detection in the nonparametric analysis. An additional
factor is the relative informativeness of the genetic
marker (D11S1324), which varied among families (data
not shown). The results from an adoption of a para-
metric approach, which is not vulnerable to these fac-
tors, also did not reveal evidence of genetic heteroge-
neity. However, these results are dependent on the
accuracy of estimated parameters, such as disease-allele
frequency, recombination fraction, and penetrance, none
of which are easily assigned to a complex trait such as
FCHL. Genetic heterogeneity is also revealed by the
comparison of our results with those seen in a separate
FCHL population. In a previous study on the Finnish
isolate, strong evidence was provided for a major FCHL
locus on human chromosome 1q21 (Pajukanta et al.
1998). However, this locus, identified on 1q21 (peak
markers D1S104 and D1S1677), did not show signifi-
cant evidence of linkage in the Dutch pedigrees reported
here.
Complex segregation analyses have been applied to
estimate the number of genes influencing FCHL, and
evidence has been presented suggesting a model with
only one or two major loci affecting serum triglyceride
levels and/or apoB levels (Cullen et al. 1994; Jarvik et
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al. 1994). Our results are consistent with a more com-
plex pattern of inheritance involving multiple genetic
factors or extensive heterogeneity. No locus with a LOD
score 13.0 was observed; therefore, it is highly unlikely
that FCHL results from a single major predisposing gene
in this Dutch population. Similarly, no locus with a LOD
score 13.0 was observed for any of the primary quan-
titative traits used in the diagnosis of FCHL, including
levels of plasma triglycerides, cholesterol, apoB, and
apoCIII (data not shown). Furthermore, these compo-
nent quantitative traits failed to reveal evidence for link-
age in regions identified by the analysis of the qualitative
FCHL phenotype. This is best exemplified in the chro-
mosome 11p candidate region, suggesting that the in-
dividual quantitative measurements may not accurately
encompass the FCHL trait and that the qualitative
FCHL phenotype may be a more accurate means of
diagnosis.
An issue confounding the genetic analysis of FCHL is
its mode of inheritance. The very large empiric risk (ap-
proaching 50% in some cases) to first-degree relatives
has suggested, to some investigators, an autosomal dom-
inant mode of inheritance. Although a number of seg-
regation analyses have yielded results inconsistent with
the dominant model, it does remain a possibility (Wil-
liams and Lalouel 1982; Jarvik et al. 1994; Bredie et al.
1996; Bredie et al. 1997b; Juo et al. 1998). One of the
potential inferences from these results is that autosomal
dominant inheritance is very unlikely as a potential ex-
planation for FCHL in the Dutch population. We did
not observe a LOD score 3.0, using a large set of
affected sibling pairs and a 10-cM-density genome scan.
Linkage analysis for an autosomal dominant locus, con-
tributing a risk to siblings (ls ) of 3.0, should yield a
LOD score of 3.3, given the large number of sibling pairs
and the extensive pedigrees in the present study (Hauser
et al. 1996). Yet, given both the empiric risk to sibs and
the population frequency, FCHL has a sibling-risk es-
timate of . Thus the results reported here con-l 1 20s
tribute to the evidence that FCHL is complex, since traits
exhibiting Mendelian inheritance would be expected to
yield a highly significant LOD score at one locus. These
results indicate that FCHL may develop from the ad-
ditive effects of many genes, a high degree of genetic
heterogeneity, or gene-gene and gene-environment inter-
actions.
To conclude, the results of this genomewide scan pro-
vide evidence for a novel region, on chromosome 11,
contributing to the FCHL phenotype in 35 Dutch fam-
ilies. At this time, chromosome 11 should still be con-
sidered a hypothesis-generating locus, and additional
families should be studied to provide definitive evidence.
It is now clear that FCHL is complex and heterogeneous,
emphasizing the need for a variety of approaches, both
biochemical and genetic, and for studies of multiple
populations.
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